Detalhe da pesquisa
1.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
N Engl J Med
; 386(1): 35-46, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34752019
2.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
N Engl J Med
; 386(20): 1910-1921, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320659
3.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
N Engl J Med
; 385(17): 1627-1629, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525276
4.
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.
Clin Cancer Res
; 30(8): 1448-1456, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100047
5.
Clinical development and approval of COVID-19 vaccines.
Expert Rev Vaccines
; 21(5): 609-619, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157542
6.
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
Vaccine
; 40(10): 1483-1492, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131133
7.
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Adv Ther
; 39(8): 3789-3798, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35771353
8.
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Cancer Discov
; 12(5): 1248-1265, 2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176764
9.
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
Lancet Reg Health West Pac
; 29: 100586, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36120090
10.
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.
Nat Commun
; 12(1): 7105, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907170
11.
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Nat Med
; 27(6): 1062-1070, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33888900
12.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Cancer Discov
; 11(1): 80-91, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988960
13.
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Clin Cancer Res
; 27(10): 2723-2733, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33622704
14.
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Leukemia
; 34(11): 2903-2913, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733012
15.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835495